← SynDRA
APTIGANEL
SynDRA canonical compound SYN0003592 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | GRIN1 |
|---|
| Mechanism of action | Glutamate receptor antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- Glutamate receptor antagonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- SIGMAR1
- ATAD5
- ATXN2
- TSHR
- TP53
- THPO
- TDP1
- PMP22
- MTOR
- MAPT
- LMNA
- KCNH2
- IDH1
- HDAC6
- GMNN
- GLS
- GBA1
- EHMT2
- DRD1
- CYP3A4
- CYP2D6
- CYP2C9
- CYP2C19
- CYP1A2
- CBX1
- USP1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- COMT
- CP2D6
- CP3A4
- CP3A7
- GAMT
- GNMT
- HNMT
- MDM2
- MDM4
- NNMT
- PNMT
- RARA
Drug classes
- Excitatory Amino Acid Antagonists
- Neuroprotective Agents
Cross-references
Synonyms
- 1-(m-Ethylphenyl)-1-methyl-3-(1-naphthyl)guanidine
- Guanidine, N-(3-ethylphenyl)-N-methyl-N'-1-naphthalenyl-
- aptiganelum
- RefChem:113564
- DTXCID0028406
- Aptiganel [INN]
- 1-(3-ethylphenyl)-1-methyl-2-naphthalen-1-ylguanidine
- 1-(3-ethylphenyl)-1-methyl-3-(naphthalen-1-yl)guanidine
- Lopac-C-4238
- UNII-46475LV84I
- APTIGANEL [MI]
- APTIGANEL [MART.]
- APTIGANEL [WHO-DD]
- Lopac0_000312
- SCHEMBL151144
- SCHEMBL151145
- orb1701185
- SCHEMBL21775476
- SCHEMBL29742194
- SCHEMBL30416816
- SCHEMBL30481113
- CHEBI:135286
- BDBM50043958
- AKOS040747835
- CCG-204407
- SDCCGSBI-0050300.P002
- NCGC00015236-01
- NCGC00015236-02
- NCGC00015236-03
- NCGC00015236-07
- NCGC00162124-01
- DA-50654
- HY-100356
- CS-0018670
- NS00120369
- T26645
- 1-(3-ethylphenyl)-1-methyl-2-(1-naphthyl)guanidine
- BRD-K63919159-003-07-0
Look up APTIGANEL in the interactive SynDRA portal →